Protalix BioTherapeutics (PLX) Competitors $2.43 +0.05 (+2.10%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$2.43 0.00 (0.00%) As of 01/31/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends PLX vs. LENZ, PLRX, VERV, DNA, IMTX, ABUS, CRGX, DNTH, OPT, and TECXShould you be buying Protalix BioTherapeutics stock or one of its competitors? The main competitors of Protalix BioTherapeutics include LENZ Therapeutics (LENZ), Pliant Therapeutics (PLRX), Verve Therapeutics (VERV), Ginkgo Bioworks (DNA), Immatics (IMTX), Arbutus Biopharma (ABUS), CARGO Therapeutics (CRGX), Dianthus Therapeutics (DNTH), Opthea (OPT), and Tectonic Therapeutic (TECX). These companies are all part of the "pharmaceutical products" industry. Protalix BioTherapeutics vs. LENZ Therapeutics Pliant Therapeutics Verve Therapeutics Ginkgo Bioworks Immatics Arbutus Biopharma CARGO Therapeutics Dianthus Therapeutics Opthea Tectonic Therapeutic LENZ Therapeutics (NASDAQ:LENZ) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, community ranking, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership. Is LENZ or PLX more profitable? LENZ Therapeutics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat LENZ Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LENZ TherapeuticsN/A -58.48% -55.50% Protalix BioTherapeutics -21.03%-30.89%-11.74% Do analysts rate LENZ or PLX? LENZ Therapeutics presently has a consensus target price of $35.40, suggesting a potential upside of 38.66%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe LENZ Therapeutics is more favorable than Protalix BioTherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable valuation and earnings, LENZ or PLX? Protalix BioTherapeutics has higher revenue and earnings than LENZ Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENZ TherapeuticsN/AN/A-$124.65MN/AN/AProtalix BioTherapeutics$65.49M2.73$8.31M-$0.13-18.69 Does the MarketBeat Community favor LENZ or PLX? LENZ Therapeutics received 2 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave LENZ Therapeutics an outperform vote while only 72.73% of users gave Protalix BioTherapeutics an outperform vote. CompanyUnderperformOutperformLENZ TherapeuticsOutperform Votes10100.00% Underperform VotesNo VotesProtalix BioTherapeuticsOutperform Votes872.73% Underperform Votes327.27% Do institutionals & insiders hold more shares of LENZ or PLX? 54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 38.4% of LENZ Therapeutics shares are held by insiders. Comparatively, 6.3% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, LENZ or PLX? LENZ Therapeutics has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Does the media refer more to LENZ or PLX? In the previous week, LENZ Therapeutics had 7 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 8 mentions for LENZ Therapeutics and 1 mentions for Protalix BioTherapeutics. LENZ Therapeutics' average media sentiment score of 0.22 beat Protalix BioTherapeutics' score of -0.42 indicating that LENZ Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryLENZ Therapeutics beats Protalix BioTherapeutics on 11 of the 16 factors compared between the two stocks. Get Protalix BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLX vs. The Competition Export to ExcelMetricProtalix BioTherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$174.51M$3.05B$5.58B$20.09BDividend YieldN/A1.84%5.32%3.64%P/E Ratio-18.6945.7689.2642.60Price / Sales2.73319.021,254.4018.56Price / Cash17.36190.0245.9620.47Price / Book5.174.125.125.90Net Income$8.31M-$40.99M$111.40M$1.02B7 Day Performance-1.22%-0.40%2.33%-0.55%1 Month Performance29.26%0.96%3.20%4.15%1 Year Performance64.75%-1.66%24.64%16.89% Protalix BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLXProtalix BioTherapeuticsN/A$2.43+2.1%N/A+67.6%$174.51M$65.49M-18.69200Gap DownLENZLENZ Therapeutics1.9632 of 5 stars$24.90+1.4%$35.40+42.2%N/A$684.61MN/A0.00110Upcoming EarningsAnalyst RevisionNews CoveragePLRXPliant Therapeutics3.901 of 5 stars$10.97+0.4%$40.50+269.4%-40.0%$667.22M$1.58M-3.2890VERVVerve Therapeutics2.2924 of 5 stars$7.84-0.9%$25.75+228.6%-29.7%$663.48M$11.76M-3.19110DNAGinkgo Bioworks0.6449 of 5 stars$11.48-10.5%$4.58-60.1%N/A$659.57M$217.11M-0.881,218News CoverageIMTXImmatics1.4468 of 5 stars$5.53-1.3%$16.67+201.7%-51.8%$659.46M$58.44M-8.37260Short Interest ↑ABUSArbutus Biopharma2.7053 of 5 stars$3.39+2.0%$5.50+62.5%+40.5%$641.42M$18.14M-7.8790CRGXCARGO Therapeutics2.7575 of 5 stars$13.84+2.8%$31.80+129.8%-83.6%$637.52MN/A-3.25116Analyst DowngradeAnalyst RevisionNews CoverageDNTHDianthus Therapeutics1.939 of 5 stars$21.32+0.5%$46.43+117.8%+16.6%$635.75M$2.83M-8.5980Short Interest ↑OPTOpthea2.6974 of 5 stars$4.64-5.2%$12.00+158.9%+105.2%$632.35M$120,000.000.008Analyst ForecastShort Interest ↑News CoverageGap UpHigh Trading VolumeTECXTectonic Therapeutic2.1261 of 5 stars$42.31-9.5%$72.25+70.8%N/A$627.95MN/A-7.23120Analyst ForecastNews Coverage Related Companies and Tools Related Companies LENZ Therapeutics Alternatives Pliant Therapeutics Alternatives Verve Therapeutics Alternatives Ginkgo Bioworks Alternatives Immatics Alternatives Arbutus Biopharma Alternatives CARGO Therapeutics Alternatives Dianthus Therapeutics Alternatives Opthea Alternatives Tectonic Therapeutic Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:PLX) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump loves DeepSeekPresident Trump could be ecstatic. And it's all thanks to DeepSeek. The secretive Chinese startup just r...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredNew catalyst on Wall Street’s radar for this week (NOT Trump)Wall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger ...Timothy Sykes | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
